Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Here's how the ASX 200 market sectors stacked up last week
Investing Strategies
How to invest in the future with ASX AI shares
ESG
The ESG investing revolution: What you need to know to profit
Dividend Investing
6 ASX 200 shares with ex-dividend dates next week
Broker Notes
3 no-brainer ASX shares to buy under $30
Share Market News
Here are the top 10 ASX 200 shares today
Broker Notes
How these 4 ASX 200 shares just gained major broker upgrades
Dividend Investing
Everything you need to know about the record Cochlear dividend
Earnings Results
Cochlear share price falls despite 29% dividend boost
52-Week Highs
Big news: 15 ASX 200 shares smashing 52-week highs this Tuesday
Share Market News
Here's how the ASX 200 market sectors stacked up this week
Share Market News
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
